A Study of the Effectiveness of Xultophy® (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 Diabetes Mellitus

Sponsor
Novo Nordisk A/S
Study ID
NCT02754817
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • insulin degludec/liraglutide — DRUG
    This is a non-interventional, chart review study and the patients are treated according to current clinical practice and local licenses upon the treating physicians' decision.

Study Details

This study is conducted in Europe. The aim of the study is to investigate the effectiveness of Xultophy® (insulin degludec/liraglutide) in an adult real-world population with type 2 diabetes mellitus.

Key Dates

Start date
Apr 26, 2016
Status verified
Jan 2018
Primary completion
Oct 20, 2016
Completion
Oct 20, 2016

Study Design

Enrollment
611 participants (actual)

Arms

  • Arm: Insulin degludec/liraglutide

Primary Outcome Measure

Change in HbA1c (Hemoglobin A1c) [ Time Frame: week 0, week 26 ]

Related Studies